logo
Indian cut & polished diamonds exports to decline by 7%-10% in FY26: ICRA

Indian cut & polished diamonds exports to decline by 7%-10% in FY26: ICRA

Time of India27-06-2025
Rating agency
ICRA
expects the Indian cut & polished diamonds (CPD) exports to further decline by 7-10% in FY2026 on a YoY basis to about $12 billion, after witnessing 20-year low exports in FY2025. This is largely attributable to pressure on demand in the US, exacerbated by uncertainties surrounding the imposition of US tariffs. ICRA has thus maintained its sector outlook at Negative.
In FY2025, CPD exports from India contracted by 17% to $13 billion, led by worsened global macroeconomic conditions and increasing competition from lab-grown diamonds (LGD) and fancy-coloured diamonds (FCD).
Driven by a shift in consumer preferences for comparatively inexpensive diamonds and their perception of LGD's ethical sourcing, these diamonds have gained momentum, with their market share increasing to 8% of polished diamond exports in FY2025 vis-à-vis 1% in FY2019.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Cardiologist Reveals: The Simple Morning Habit for a Flatter Belly After 50!
Lulutox
Undo
While the prices of rough diamonds declined by 8% in FY2025 as miners implemented price cuts to boost demand, any considerable correction in rough prices in the near term is unlikely. Miners are expected to curtail their production output in FY2026; controlled supply shall keep rough prices at their current level.
Polished diamond prices dropped to an all-time low in H2 FY2025, as demand remained tepid, resulting in the polished diamond prices in FY2025 declining by 7% YoY, after a 17% YoY fall in FY2024.
Live Events
Q1 is generally a slow quarter for the industry, which, coupled with the evolving tariff situation, is expected to result in range-bound polished prices in H1 FY2026.
In FY2025, the operating profit margin (OPM) of ICRA's sample set of CPD companies declined by around 400 basis points to 4%, led by negative operating leverage. ICRA expects the OPM for entities in its sample set of companies to decline further to 3.6-3.7% in FY2026, as the extent of passing on the price increases led by US tariff imposition remains limited in the backdrop of restrained demand.
The credit profile of Indian CPD players is likely to remain subdued in FY2026 amid reduced earnings and a stretched working capital cycle. Going forward, inventory management will remain critical from the credit perspective.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US tariffs should not be cause for disengaging from trade talks, blocs
US tariffs should not be cause for disengaging from trade talks, blocs

Business Standard

timea minute ago

  • Business Standard

US tariffs should not be cause for disengaging from trade talks, blocs

The fundamental challenge for the Indian economy is to increase productivity and competitiveness premium Business Standard Editorial Comment Mumbai Listen to This Article The tariff rate of 25 per cent, which United States (US) President Donald Trump has decided will be applied to Indian exports to the US, may not, eventually, be the final rate. It may effectively wind up being higher if he carries out his threat to add a surcharge related to India's increasing purchases of Russian oil. It may be lower if New Delhi's negotiators pull some sort of a broader deal together. It is also worth remembering that there will be multiple exceptions to this headline tariff rate. Some goods that compose a large part of India-US trade —

Collaboration for future: Isro and India will benefit from Nasa
Collaboration for future: Isro and India will benefit from Nasa

Business Standard

timea minute ago

  • Business Standard

Collaboration for future: Isro and India will benefit from Nasa

Artemis signup allows Isro and the fast-growing Indian aerospace sector to bid for Nasa tenders and the famously frugal Indian engineering sector could find opportunities there and pick up new skills Business Standard Editorial Comment Mumbai Listen to This Article The successful launch of the Nisar (Nasa-Isro Synthetic Aperture Radar) satellite from the Satish Dhawan Space Centre marks the second big mission where the two space agencies have joined hands, coming soon after gaganaut Shubhanshu Shukla travelled to the International Space Station on the Axiom 4 mission. This may be the precursor to more cooperation between the agencies, given that India in 2023 signed up for the Artemis Accords. The Artemis Accords provide a common set of principles for civil exploration and use of outer space. While both agencies benefit from cooperation, the Indian Space Research Organisation (Isro) may benefit

How Trump tariffs could impact Indian pharma's $8.7 bn dream run
How Trump tariffs could impact Indian pharma's $8.7 bn dream run

India Today

time18 minutes ago

  • India Today

How Trump tariffs could impact Indian pharma's $8.7 bn dream run

For long, the high-value US market has driven the growth of the storied Indian generic drugs industry, where companies like Cipla, Sun Pharma and Dr Reddy's Laboratories, among others, have successfully challenged hundreds of off-patent drugs in the US and established a soaring business FY24, India exported $8.7 billion (Rs 76,113 crore) worth of pharma products to the US, which comprises over 11 per cent of India's total merchandise exports to that the same period, India exported $77.5 billion (Rs 6.8 lakh crore) worth of merchandise goods to the US and imported $42.2 billion (Rs 3.7 lakh crore) worth of goods from it, resulting in a trade surplus of $35.3 billion (Rs 3 lakh crore) in India's US is India's largest destination for pharma exports, accounting for over 31 per cent of the country's total pharmaceutical exports. As much as 47 per cent of all generics consumed in the US are imported from India. However, the Donald Trump administration's threat of imposition of a 25 per cent reciprocal tariff from August 1 (up from 0 to 6.7 per cent at present) has thrown the Indian pharma industry in a bind. Shares of Indian pharma companies, led by Sun Pharma, fell close to 6 per cent on the NSE (National Stock Exchange) on August 1 following president Trump's statements on the tariff imposition, and his letters to 17 top US pharma companies asking them to reduce their rates in line with what prevailed in other countries. Some fear Trump may send a similar letter to Sun Pharma, which earns as much as 20 per cent of its total revenues from the US Indian industry was hoping against hope that Trump would not hike tariffs on generic drugs since these are life-saving. However, Trump had indicated earlier this year too that tariffs on pharma products would be 25 per cent from April 2 onwards, without pinpointing any nation. He later gave a 90-day reprieve to countries, and the new deadline for the tariffs was put as August imports roughly $800 million worth of pharmaceutical products from the US, and imposes a tariff of 10 per cent. Experts say that even if higher tariffs are imposed on active pharma ingredients (APIs), which are raw materials going into pharma production, India could still be competitive, if tariffs on other API-supplying countries are higher than that of the US will still be dependent on countries like India since the cost of manufacturing certain drugs in the US would be at least six times compared to that of manufacturing the same product in India, say industry US market, which relies heavily on India for APIs and low-cost generics, would struggle to find alternatives, according to Namit Joshi, chairman of Pharmexcil (Pharmaceuticals Export Promotion Council of India). 'Efforts to shift pharmaceutical manufacturing and API production to other countries or within the US will take at least 3-5 years to establish meaningful capacity,' he was quoted in media reports. advertisement'There is no need for panic. The industry should lie low for now since the US has not yet increased the tariffs. Who else can give the US such competitively-priced goods in large quantities and high quality?' Daara Patel, secretary general of the Indian Drug Manufacturers Association, had said in an interview to INDIA TODAY in April. 'Even if it increases up to 10 per cent, the industry should be able to absorb it or pass it on to the US consumers. They would not mind paying for it since it all works on insurance money,' he what if the US decides to go for a higher tariff? 'In case the US raises tariffs beyond 15 per cent, India will have to look at newer markets in East Africa and the Middle East. These markets are neither high value nor high in volumes, but it will be a better option than dealing with an uncertain US market alone,' Patel had saidSubscribe to India Today Magazine- EndsTune InMust Watch

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store